IP Library Granted Patent US 8,388,610
Granted Patent B2
US 8,388,610 · App. 12/962,318 · Granted Mar 5, 2013

Treatment pattern monitor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,388,610
App. No.
12/962,318
Granted
Mar 5, 2013
Kind
B2
Abstract

The invention relates to an apparatus and a method for determining the applicability of a treatment pattern for manipulation of a cornea of an eye using a laser. The concept of the present invention is based on the determination of an actual volumetric profile based on a set of input data and a theoretical volumetric profile which is created independently based on only the basic optical parameters. On the basis of a comparison of the determined volumetric profiles it is determined whether the actual volumetric profile is within predetermined tolerances.

Claims (19)

1. A computer system for determining the applicability of a treatment pattern for manipulation of a cornea of an eye using a laser, the computer system capable of:

(a) receiving input data corresponding to a desired refractive correction and developing a treatment pattern from the input data;

(b) developing an actual volumetric profile from the treatment pattern;

(c) receiving a theoretical volumetric profile wherein the theoretical volumetric profile is based on the input data and developed from a basic theoretical model; and

(d) comparing the actual volumetric profile with the theoretical volumetric profile to determine whether the actual volumetric profile is within specified tolerances on the basis of the theoretical volumetric profile.

2. The system of claim 1 , wherein the theoretical model uses a number of basic parameters, and wherein the computer system is further capable of determining a first theoretical volumetric profile when using the basic parameters of the theoretical model and determining a second theoretical volumetric profile using said theoretical model wherein at least one of the number of basic parameters is modified.

3. The system of claim 2 , wherein the computer system is further capable of comparing the actual volumetric profile with the first theoretical volumetric profile which serves as a minimum estimator and comparing the actual volumetric profile with the second theoretical volumetric profile which serves as a maximum estimator.

4. The system of claim 3 , wherein the computer system is further capable of modifying at least one of the basic parameters to determine a limit of a potential over or under correction of the actual volumetric profile.

5. The system of claim 2 , wherein the basic parameters are at least one of a maximum ablation depth, a central ablation depth, a treatment area, an ablation volume, an amount of correction in diopters of the volumetric pattern, a difference and/or ratio of a central ablation depth and an ablation depth in a defined area, or a difference and/or ratio of minimum or maximum ablation depth in defined areas.

6. The system of claim 1 , wherein the computer system is further capable of determining whether the actual volumetric profile corresponds to the desired refractive correction.

7. The system of claim 1 , wherein the basic theoretical model is a toric or nontoric thin lens formula.

8. The system of claim 7 , wherein the computer system is further capable of modifying an amount of correction in diopters and/or an optical zone of the thin lens formula to approximate the theoretical volumetric profile to the actual volumetric profile.

9. The system of claim 8 , wherein the amount of correction in diopters is one of ±1.0 D, ±0.5 D, ±0.33 D or ±0.25 D.

10. The system of claim 8 , wherein the modification of the optical zone is one of 1.00 mm, 0.75 mm, 0.50 mm or 0.25 mm.

11. The system of claim 1 , wherein the specified tolerance is a fixed tolerance, preferably at least one of a tolerated deviation in sphere, cylinder, axis, and optical zone.

12. The system of claim 1 , wherein the specified tolerance is a minimal tolerance, preferably by optimizing the tolerated deviation in sphere, cylinder, axis and optical zone to provide the minimal deviation from the actual volumetric profile.

13. The system of claim 1 , wherein said computer system is a laser treatment system.

14. The system of claim 1 , wherein said computer system includes a treatment calculator.

15. The system of claim 14 , wherein the treatment calculator determines a treatment pattern from diagnostic data.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →